Title: Method for the treatment of lymphedema using
United States Patent: 6,436,448
Issued: August 20, 2002
Inventors: Yue; Samuel K. (Edina, MN)
Assignee: Sky BioHealth Solutions, Inc. (Eden Prairie, MN)
Appl. No.: 891136
Filed: June 25, 2001
A novel method for preventing and treating lymphedema and for inducing
weight-loss in a patient having an elevated protein concentration in the
patient's by administering a therapeutically effective amount of guaifenesin
or its analog to the patient. In one embodiment, the method further includes
administering in the patient's diet an enzyme supplement chosen to increase
the ability of the patient's gastrointestinal tract to digest food and
administering to the patient an effective amount of relaxin hormone.
SUMMARY OF THE INVENTION
The present invention is based upon the recognition that a relationship
exists between the porosity (altered permeability or changed selectivity)
of a person's gastrointestinal tract ("GI tract") and its diseased ability
to absorb partially-digested food (macronutrients, in the form of
partially digested proteins or large clumps of amino acid) to the
accumulation of high protein fluid in a patient's tissues resulting in
weight gain and lymphedema.
Accordingly the ideal treatment for this type of lymphedema comprises: (1)
restoring the selectivity or altered permeability of the mucosa within the
linings of the GI tract, thus, reducing its ability to absorb partially
digested proteins; and (2) treating the previously accumulated high
protein edema or lymphedema.
In accordance with one aspect of the invention it has been surprisingly
found that guaifenesin is useful in reducing the accumulation of fluid in
a patient's tissue and in the treatment of lymphedema.
In one method of the invention, the accumulation of fluids in the tissue
of a patient having such accumulation is reduced by administering to the
patient a therapeutically effective amount of guaifenesin or one of its
pharmaceutically acceptable derivatives. In one embodiment of the method,
the amount administered is about 600 mg to about 4000 mg per day.
In one preferred embodiment of the invention, the guaifenesin or its
pharmaceutically acceptable derivative is administered to the patient in
two different dosage forms, one dosage form being a short acting form and
the other being a long acting form. The short acting dosage is preferably
about 200-600 mgs and the long acting form is preferably about 200-600
mgs. The two forms are desirably administered to the patient once or twice
a day so that a sustained level of guaifenesin or its pharmaceutically
acceptable derivative may be obtained in the blood stream sufficient for
the lymphatic diuresis to occur.
In other embodiments of the invention, the guaifenesin or its
pharmaceutically acceptable derivative may be administered to the patient
in more than one dose of a short acting dosage form or in different
combinations of short acting doses with long acting doses. Some reduction
of fluid accumulation will be seen with the administration of guaifenesin
in the amounts described herein in most patients, however, the dosage
regime should be optimized for each patient.
Another embodiment of the invention is a method for inducing weight loss
in patients having accumulated fluid in their tissue comprising
administering an effective amount of guaifenesin or one of its
pharmaceutically acceptable derivatives to a patient to cause a reduction
in the amount of the accumulated fluid and weight loss.
Yet another embodiment of the invention is a method for treating and
preventing lymphedema comprising the steps of: a) using guaifenesin or one
of its pharmaceutically acceptable derivatives to reduce accumulated high
protein fluid in a patient; b) including in the patient's diet, enzyme
supplements chosen to increase the ability of the patient's
gastrointestinal tract to digest food; and c) administering to the patient
an effective amount of relaxin and its related hormones to induce
production of new collagen to repair the mucosa and restore the
selectivity of the gastrointestinal tract.
Claim 1 of 17 Claims
What is claimed is:
1. A method for treating lymphedema in a patient comprising administering
a therapeutically effective amount of guaifenesin to the patient in two
different dosage forms.
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full